Bullish Case: Known: GENI ~$7.31 with call volume > puts and backwardation; Helium return-surface mass concentrates on small positive/mean-reverting returns across holding years. My earlier mid-July 6.8–7.6 is near-target, but the $10–$12 tail hasn’t arrived. Inferred: with no new financing stress, odds favor a grind toward modest upside as event-premium IV bleeds. Uncertain if guidance/refi stays non-dilutive.

Bearish Case: Known: downside IV is priced (GENI puts on lower strikes carry similar-to-higher IV; SPY IV surface shows persistent downside skew into bad states). Inferred: return surface still permits sizable negative tails, and my earlier $10–$12 bullish calls missed, so catalysts/timing dominate mean reversion. Uncertain: leverage/contract disputes triggering refinancing-dilution or major rights loss.

Potential Outcomes:

1. 40%: 8–9.5 (return-surface small+ density + mean-reversion; falsify on covenant/refi dilution headline, incl. next earnings).
2. 15%: 10–12 (confirmed premium exit/buyout or sustained guidance upgrades).
3. 25%: 6–8 (no major news; IV cools while spot mean-reverts).
4. 20%: <6 (equity-raise/covenant stress or major contract/governance shock; could extend to <4).

Oracle: track GENI spot vs IV/skew; if IV stays elevated while price fails to trend up, tail-risk dominates.

July 29, 2026